Also known as: Reta
Molecular Weight
4112 Da
Half-Life
6 days
Administration
Subcutaneous injection
Longevity Score
8/10
A novel unimolecular triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon (GCG) receptors. Promotes satiety, enhances insulin sensitivity, increases energy expenditure via glucagon receptor activation, and significantly reduces liver fat.
beginner
1mg weekly
intermediate
4mg weekly
advanced
8-12mg weekly
athlete
4-8mg weekly
Frequency: Once weekly · Duration: 24–48 weeks with gradual dose titration (1mg → 4mg → 8mg → 12mg every 4 weeks)
Week 1-2
Reduced appetite, possible GI adjustment
Week 3-4
Noticeable weight loss begins
Week 5-8
Significant fat reduction, liver fat normalization
Long Term
Metabolic optimization, up to 24% weight reduction at 48 weeks
TRIUMPH-2 Phase 3 Trial (2024)
Achieved 24.2% weight loss at 48 weeks with highest dose
DOI: 10.1038/s41591-024-03018-2Explore more peptides in this category
View All Metabolic Peptides →Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.